SINGLE-USE BIOREACTOR MARKET ANALYSIS

Single-Use Bioreactor Market Size and Trends

The Single Use Bioreactor Market is estimated to be valued at USD 3.51 Billion in 2024 and is expected to reach USD 11.2 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 18% from 2024 to 2031.

To learn more about this report, request sample copy

The market growth is driven by growth in the biopharmaceutical industry and advantages of single-use technologies over stainless steel bioreactors. The trend in the single use bioreactor market has been rising adoption rates across small companies and contract manufacturing organizations. Traditionally, large biopharma companies were the primary adopters of single-use bioreactors due to high capital investment required for stainless steel bio reactors. However, small biotech startups and contract pharma manufacturing players now see single-use bioreactors as advantageous due to low installation and maintenance costs. This has allowed these entities to benefit from the flexibility of single-use bioreactors. Going forward, this trend is expected to continue and drive the market growth during the forecast period.

Advancements in Single-Use Bioreactors

The demand for single-use bioreactors is growing significantly among pharmaceutical companies as they look to streamline their drug production processes. A major driver pushing this adoption is the operation and manufacturing advantages offered by single-use bioreactors over their stainless-steel counterparts. Pharmaceutical companies are dealing with greater regulatory requirements today to ensure drug safety and quality. With single-use bioreactors, they can reduce the risks of cross-contamination between different drug batches as each bioreactor is used only once. This helps improve compliance with stringent cGMP guidelines.

Noteworthy advancements are underway in the single-use bioreactor sector, driving the market expansion. For instance, in March 2021, Thermo Fisher Scientific introduced the 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors. These vessels share the same footprint, featuring simplified hardware optimized for perfusion cell culture processes, thereby aiding in conserving manufacturing suite space. These advancements are expected to propel the market growth in the foreseeable future.

Rising Demand for Increased Bioproduction Capacity

Global demand for biologics has grown substantially in recent years, driven by the expanding markets for vaccines, monoclonal antibodies, and other biomolecules. As biopharmaceutical pipelines continue delivering promising new drug candidates, the need to scale up biomanufacturing capabilities is increasingly crucial. However, building additional stainless-steel facilities requires sizable capital investments and can take 2-3 years to complete. In contrast, single-use bioreactors provide a faster and more cost-effective means to accelerate bioproduction without significant facility expansion. Their implementation can help gain vital biomanufacturing capacity within a much shorter timeframe to better address market needs. By offering a highly scalable approach, single-use bioreactors have enabled facilities to smoothly transition production volumes across different batch and product sizes. Their modular, standardized design allows for more predictable scale-up studies compared to conventional systems.